Is Eli Lilly (LLY) Halal? Full Faith-Screening Breakdown

Ask "is Eli Lilly halal" and you will get two confident and opposite answers depending on which index provider someone happens to be quoting. That is not a scholarly dispute about pharmaceuticals. It comes down to a single arithmetic choice buried in the methodology documents, and LLY happens to sit right on the wrong side of it. Here is the whole picture, with the actual numbers.

What Eli Lilly Actually Sells

Lilly is an Indianapolis pharmaceutical company founded in 1876, and since spinning off Elanco Animal Health in 2018 and 2019 it has been a pure human-pharma business. Lilly reports as one operating segment, so you do not get clean segment margins, but the revenue categories tell you plenty.

The dominant category is cardiometabolic health, which is where tirzepatide lives. Mounjaro (type 2 diabetes) and Zepbound (obesity and obstructive sleep apnea) are the same molecule sold under two labels, and between them they are the reason LLY's trailing revenue is roughly $72 billion, up something like 47% year over year. Around them sit Trulicity, the Humalog and Humulin insulin franchise, and Jardiance, which Lilly co-promotes with Boehringer Ingelheim.

The rest breaks into oncology (Verzenio, Jaypirca, Retevmo), immunology (Taltz, Omvoh, Ebglyss, Olumiant), and neuroscience, where Kisunla for early symptomatic Alzheimer's is the headline product. Cialis is still on the books but has been generic for years and no longer moves the needle.

The non-compliant revenue line

For a Shariah screen the question is what share of that $72 billion comes from prohibited activity. Lilly sells no alcohol, no tobacco, no gambling, no conventional financial services, no pork products. It has no defense division and no hotel or entertainment exposure. The only meaningful non-permissible income is interest earned on corporate cash and investments, which shows up inside other income rather than revenue. Against a $72 billion top line that is a rounding error, comfortably inside the 5% ceiling that AAOIFI, Dow Jones Islamic Market and S&P Shariah all apply.

The Financial Ratio Screen

This is where LLY gets interesting, and where the answer genuinely splits.

Debt

As of the most recent balance sheet, Lilly carries about $43.4 billion of total interest-bearing debt: roughly $4.0 billion short term and $39.4 billion long term. That is a lot of bonds, and it has been growing, because Lilly has been funding an enormous manufacturing buildout to keep up with tirzepatide demand.

Now the denominator. Lilly's market capitalization is around $1.02 trillion at a share price near $1,149. Total assets are about $116.6 billion.

• Debt divided by market cap: about 4.3%
• Debt divided by total assets: about 37.2%

One of those numbers passes a 30% screen with almost 26 points to spare. The other fails a 33.33% screen outright.

Cash and interest-bearing securities

Cash and short-term investments run about $5.3 billion. Against market cap that is roughly 0.5%, which is nowhere near any threshold. Against total assets it is about 4.5%, still fine. This ratio is a non-event for LLY in every methodology, mostly because Lilly runs a lean cash balance and funds itself with debt instead.

AAOIFI also applies a receivables test (accounts receivable relative to the relevant denominator, with 45% as the usual cap). Lilly's receivables are a modest slice of a $116.6 billion asset base and an invisible one against a trillion-dollar market cap, so this one clears easily too.

Where the Screens Disagree, and Why

The 30% and 33% figures get quoted as if they were one rule. They are three rules wearing similar clothes.

AAOIFI Shariah Standard No. 21 caps interest-bearing debt at 30% of market capitalization. LLY at 4.3% passes.

Dow Jones Islamic Market uses 33% of trailing 24-month average market cap. Lilly's stock has run hard, so the 24-month average is meaningfully lower than today's price, but even halving the denominator leaves the ratio under 10%. LLY passes.

S&P Shariah also uses market cap in the denominator. LLY passes.

FTSE Shariah and MSCI Islamic use total assets instead. Both cap debt at 33.33% of total assets. LLY at roughly 37.2% fails.

So a Muslim investor who follows Sheikh Nizam Yaquby's methodology as implemented in DJIM gets a pass, and one who holds an FTSE Shariah or MSCI Islamic tracker finds LLY absent from the index. Neither party is being sloppy. The market-cap denominator asks whether the market's valuation of the enterprise dwarfs its borrowing. The total-assets denominator asks whether the company's own book is levered, and deliberately ignores what the market thinks, precisely because market caps inflate and deflate on sentiment. Lilly is the textbook case where those two questions diverge, because the market values Lilly at nearly nine times its book assets.

If you want to see which methodology a given verdict is running on before you trust it, the framework comparison on FaithScreener lays the denominators and thresholds side by side.

Pork Gelatin, Porcine Insulin and the Ingredient Question

Every "is Eli Lilly halal" thread eventually reaches gelatin, so let us separate two different questions.

The first is whether a Muslim patient may swallow a capsule with a porcine gelatin shell. That is a fiqh question about consumption, and the mainstream answer leans permissive under two arguments: istihalah, the transformation of a substance into something chemically distinct, and darura, necessity, where no halal alternative exists. The Islamic Fiqh Academy in Jeddah has addressed medical necessity in this vein, and many contemporary muftis permit gelatin-shelled medication where a substitute is unavailable while preferring vegetarian HPMC capsules when one exists.

The second question is whether gelatin content makes the stock non-compliant. It does not, under any of the four methodologies above. Screens look at revenue derived from prohibited activity, not at excipients in the supply chain. Gelatin is a purchased input costing pennies, not a revenue line.

Worth knowing as history: Lilly commercialized the first insulin in 1923 under the Iletin brand, extracted from pig and cattle pancreases. That porcine-derived product line is long discontinued. Humalog, Humulin and the rest of the modern portfolio are recombinant DNA products made in engineered bacteria or yeast, with no animal tissue in the manufacturing path.

The Christian BRI Verdict

Biblically Responsible Investing screens (Inspire, eVALUEator and the Timothy Plan family being the common implementations) run six broad categories: abortion, alcohol, tobacco, gambling, pornography, and advocacy or human-rights concerns depending on the provider.

Lilly clears alcohol, tobacco, gambling and pornography without discussion. The abortion category is where it gets flagged, and for two distinct reasons that BRI providers weigh differently.

The first is R&D methodology, covered below under the Catholic lens, since the underlying fact pattern is the same. The second is corporate advocacy. In August 2022 Lilly publicly criticized Indiana's abortion restriction and said it would plan future growth outside its home state, a well-documented and openly stated corporate position. Lilly also scores at the top of the HRC Corporate Equality Index. Screens that only measure products and services will not register either of those. Screens that explicitly weigh corporate advocacy, and several BRI providers do, will downgrade or exclude LLY on both counts. If you use a BRI screen, check whether advocacy is in scope before you assume a verdict.

The Catholic USCCB Verdict

The USCCB Socially Responsible Investment Guidelines exclude direct involvement in abortion, contraception, embryonic stem cell research and human cloning, alongside the usual tobacco, weapons and pornography categories.

Lilly does not market a contraceptive or abortifacient franchise, which removes the most direct exclusion. The live issue is R&D that touches cell lines of fetal origin. HEK293 and similar immortalized lines are ubiquitous in biologics discovery and testing across the entire industry, and a large-molecule pipeline like Lilly's is very unlikely to be entirely free of them somewhere in preclinical work.

Catholic teaching here is more nuanced than a simple exclusion. Dignitas Personae (2008) and subsequent guidance from the National Catholic Bioethics Center treat the use of products with remote historical connection to such lines as materially cooperative rather than formally cooperative, permissible when no alternative exists, coupled with a duty to make the objection known and to press for alternatives. A USCCB-aligned screener will typically not exclude Lilly outright on this basis alone, but a Catholic institutional investor following the guidelines closely would be expected to engage the company rather than simply hold quietly.

The Jewish Halakhic Verdict

Two questions matter here, and neither concerns the medicines.

Ribbis is the first. Lilly is a borrower at interest on a $43 billion scale and earns interest on its cash. Under the two-tier analysis used by Bais HaVaad and similar poskim, a minority shareholding in a publicly traded corporation controlled by non-Jews does not make the shareholder a principal to those loans, and where the concern does bite, a heter iska structure is the standard remedy. Held in an ordinary brokerage position, LLY presents no meaningful ribbis problem.

The second is kashrut, and it does not apply. Owning equity in a company whose products contain gelatin is not consumption. On top of that, pikuach nefesh overrides kashrut for genuinely needed medication anyway. A Torah-observant investor screening for LLY is functionally screening for the same things the general market screens for: business conduct, honest dealing, and whether the leverage is prudent.

The LDS Verdict

There is no formal Church-published exclusion list, and Ensign Peak's public filings show broad index exposure that would include a mega-cap like Lilly by construction. The Word of Wisdom concerns alcohol, tobacco, coffee and tea, none of which touch a pharmaceutical maker.

The one genuinely LDS-flavored caution is Dallin H. Oaks' 1971 warning against speculation as distinct from investment. LLY trades near 41 times earnings after a 42% run, priced on the assumption that oral GLP-1 candidates like orforglipron land and that tirzepatide keeps compounding. Buying it because the chart is going up is the behavior Oaks was describing. Buying it because you have a view on the pipeline and a decade-long horizon is not.

Purification: What You Would Actually Owe

If you take the market-cap methodology and hold LLY as compliant, the AAOIFI-style obligation is to purify the portion of your return attributable to interest income. Note the direction: you purify interest the company earns, not interest it pays. Lilly's $43 billion of debt costs it money and does not create a purification obligation.

The method most scholars apply is to take the company's interest and investment income as a share of net income, then apply that percentage to the dividends you received (some scholars extend it to realized capital gains as well). Lilly's cash balance is small, roughly $5.3 billion against $25.3 billion of net income, so interest income is a thin slice of earnings, plausibly in the low single digits of a percent.

Run the arithmetic on the current $6.92 annual dividend and you are looking at somewhere on the order of ten to twenty cents per share per year to donate. Treat that as an order-of-magnitude estimate rather than a precise figure. Pull the actual "other income (expense), net" line from Lilly's most recent 10-K and split out the interest component before you calculate, because the correct number changes every year and Lilly's investment income has been moving as its cash balance shifts.

What Could Flip the Verdict

Four things, in descending order of likelihood.

The total-assets ratio getting worse. LLY already fails the FTSE and MSCI screen at about 37% of assets. Lilly has committed to a very large domestic manufacturing expansion, which it is partly debt-funding. New plant assets raise the denominator and new bonds raise the numerator, so the direction of travel depends on which grows faster. This ratio is the one to watch quarterly.

A market-cap collapse. For the AAOIFI 30% test to fail on $43.4 billion of debt, Lilly's market cap would have to drop below roughly $145 billion, an 85%-plus decline. A GLP-1 competitive shock or a clinical failure could hurt the stock badly without getting anywhere near that.

An acquisition. Lilly has been an active buyer. A deal that adds a contraceptive line, a large financing arm, or a business with material non-permissible revenue would change the qualitative screen, not just the ratios.

Methodology revision. If your index provider changes its denominator, your verdict changes overnight with no news from Indianapolis at all.

Checking Eli Lilly's Live Verdict

Ratios move every quarter, and debt-heavy capex stories move faster than most. The live LLY screening page recomputes the debt, cash and non-permissible income ratios against current filings and market data, and shows the verdict separately under each methodology rather than collapsing them into one answer. You can run the same comparison against Pfizer, Merck, Novo Nordisk or any other name through the screening tool if you want to see how LLY's leverage stacks up inside the sector.

The Bottom Line

Eli Lilly passes the Shariah screen under AAOIFI, Dow Jones Islamic Market and S&P Shariah, where debt is measured against a trillion-dollar market cap and lands near 4%. It fails under FTSE Shariah and MSCI Islamic, where the same $43.4 billion is measured against $116.6 billion of total assets and lands around 37%. The business itself is clean on qualitative grounds across all of them, gelatin included. Under the Christian BRI lens the sticking points are R&D cell lines and corporate advocacy rather than products; under USCCB guidelines the fetal-cell question calls for engagement rather than automatic exclusion; halakhically the ribbis exposure is remote and heter-iska-addressable; and the LDS concern is valuation discipline rather than the company. The single thing to remember about LLY specifically: your verdict is decided by which denominator your methodology uses, so find that out first.

This is educational research rather than a religious ruling or personalized investment advice, and you should confirm your own position with a qualified scholar or advisor.